Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 19 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.